S

Sanofi

Global pharma company; vaccines and R&D

Website

Overview

Sanofi is a global pharmaceutical and biotechnology company that develops, manufactures, and sells prescription medicines, over-the-counter products, and vaccines. Its products span immunology, oncology, rare diseases, and vaccines, addressing unmet medical needs through a strong focus on research and development. Sanofi's core product model relies on large-scale R&D, strategic partnerships, and licensing to bring new therapies to markets, with revenue generated from product sales and collaborations. The company differentiates itself by leveraging its global reach, diverse portfolio, and emphasis on patient-centric solutions, safety, and quality to navigate regulatory environments in developed and emerging markets. The company’s goal is to improve health outcomes and quality of life for people worldwide by delivering innovative treatments and vaccines that meet unmet medical needs.

Work here?Claim your company

About Sanofi

Simplify's Rating
Why Sanofi is rated
B
Rated B on Competitive Edge
Rated A on Growth Potential
Rated C on Differentiation

Industries

BiotechnologyHealthcare

Company Size

10,001+

Company Stage

IPO

Headquarters

Paris, France

Founded

1973

Get referred to Sanofi

See people who can refer or advise you

Simplify Jobs

Simplify's take

What believers are saying

  • July 10, 2026 FDA approval of Sarclisa Escena created the first on-body cancer injector.
  • June 13, 2026 FDA accelerated approval expanded Tzield into recently diagnosed stage 3 T1D.
  • Q2 2026 sales grew 17.8% at CER, with Dupixent and Beyfortus leading.

What critics are saying

  • Texas sued Sanofi on February 19, 2026 over provider bribery and Medicaid fraud.
  • Sanofi sued Pfizer and Moderna on July 15, 2026, extending costly mRNA patent warfare.
  • Dupixent concentration makes 2030s patent loss an existential revenue shock.

What makes Sanofi unique

  • Dupixent reached €5.2 billion quarterly sales in Q2 2026 across nine indications.
  • October 1, 2026, Sanofi and Regeneron added four long-acting antibodies to their Alliance.
  • Sanofi's 61-project pipeline spans immunology, rare diseases, vaccines, neurology, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Funding

Total Funding

$9.4B

Above

Industry Average

Funded Over

8 Rounds

Grant funding comparison data is currently unavailable. We're working to provide this information soon!
Grant Funding Comparison Coming Soon

Benefits

  • Health Insurance
  • Professional Development Budget
  • Parental Leave

Stock Price

Company News

Yahoo Finance
Nov 3rd, 2026
Nurix shares plunge 35% after Sanofi ends drug programme worth up to $455M in milestones

Shares of Nurix Therapeutics (NRIX) fell 35% after hours on Tuesday, after partner Sanofi ended development of SAR448272, an experimental oral drug it licensed from Nurix. Sanofi is terminating the early-stage first-in-human trial. The compound was being studied for type 2 inflammatory and autoimmune conditions such as atopic dermatitis and asthma. The decision ends roughly $455 million in potential milestone payments, plus royalties, tied to the program. Nurix has received about $139 million from Sanofi under their 2019 deal, including $10 million when the trial began this year. Nurix said its cash runway guidance is unchanged. It held $1.1 billion in cash, cash equivalents, and marketable securities as of August 31, which it expects will fund operations into the second half of 2029.

Yahoo Finance
Oct 30th, 2026
Sanofi shares jump 6% as it raises 2026 outlook and signals appetite for bigger deals

Sanofi shares jumped nearly 6% on Friday after the drugmaker raised its 2026 outlook and said it is open to larger deals. The company now expects sales to grow in the low teens this year, with business earnings per share up in the mid-teens at constant exchange rates. Third-quarter sales rose 14.3% to 14.44 billion, and operating income was 5.43 billion. Dupixent remained the main growth driver, with sales up 34.8% to 5.7 billion. New medicines added 1.4 billion. Chief financial officer Francois Roger said Sanofi could consider deals above its typical $2 billion to $5 billion range. The company continues to focus on immunology, rare diseases, and vaccines.

Yahoo Finance
Oct 30th, 2026
Sanofi lifts 2026 guidance as Q3 sales rise 14.3% to $15.6B on Dupixent strength

Sanofi reported third-quarter sales of €14.4 billion, up 14.3% at constant exchange rates, and raised its 2026 outlook. Business operating income rose 19.7%, while business EPS increased 19.6%. The company now expects 2026 sales growth of 13% to 15% and business EPS growth of 15% to 17%. Dupixent sales hit €5.7 billion, with more than 1.5 million patients treated worldwide. Sanofi still targets Dupixent sales of €25 billion by 2030. Sanofi is focusing on immunology, rare diseases, and vaccines. It discontinued two development programmes and expanded its Regeneron alliance to four next-generation antibodies. Planned divestments are expected to cut 2027 sales by about €1.3 billion.

Yahoo Finance
Oct 30th, 2026
Sanofi raises 2026 guidance after Q3 sales rise 14.3% to $15.6B, with Dupixent up 34.8%

Sanofi raised its 2026 guidance after third-quarter sales grew 14.3% at constant exchange rates (CER) to €14,444 million. Business earnings per share (EPS) rose 19.6% at CER to €3.55. The company now expects full-year sales to grow by a low-teens percentage at CER, and business EPS by a mid-teens percentage. Dupixent sales rose 34.8% to €5.7 billion. Sales of newly launched drugs, including ALTUVIIIO, Ayvakit, and Rezurock, climbed 31.4% to €1.4 billion. Vaccines sales fell 6.6% to €3.2 billion. Selling and general expenses fell 0.9% to €2.3 billion. Research and development spending was broadly stable at €1.8 billion. Chief executive officer Belén Garijo said the company's priority is to protect earnings when Dupixent loses exclusivity.

PR Newswire
Oct 29th, 2026
Novavax earns $125M milestone as Sanofi starts Phase 3 flu-COVID vaccine trial

Novavax has earned a $125 million milestone payment after Sanofi dosed the fifth patient in a Phase 3 trial of an influenza-COVID-19 combination vaccine in Europe. The trial tests the safety and immune response of Novavax's COVID-19 vaccine, Nuvaxovid, combined with Sanofi's Efluelda/Fluzone High-Dose flu vaccine in adults aged 60 and older. Novavax could receive a $75 million milestone once manufacturing technology transfer is completed, expected in mid-2027. It is also eligible for $225 million upon a US launch of a combination vaccine, plus royalties on Sanofi sales. "To date, the partnership has generated over $1 billion in revenue for Novavax," said chief executive officer John C. Jacobs.

Recently Posted Jobs

Sign up to get curated job recommendations

Sanofi is Hiring for 978 Jobs on Simplify!

Find jobs on Simplify and start your career today

Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs